Sun Pharma Advanced Research Company (SPARC) and Schrodinger have entered into a research collaboration to accelerate the discovery of novel CNS therapeutics by leveraging Schrodinger's advanced computational platform and SPARC's extensive drug development expertise and insights in neurodegeneration.
Schrodinger, a privately held company committed to revolutionizing drug discovery through advanced molecular simulation, will focus on lead discovery and optimization.
SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
